<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923594</url>
  </required_header>
  <id_info>
    <org_study_id>NLS-1021</org_study_id>
    <nct_id>NCT04923594</nct_id>
  </id_info>
  <brief_title>Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy</brief_title>
  <official_title>A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NLS Pharmaceutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NLS Pharmaceutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, multicenter trial of NLS-2 in adult&#xD;
      patients with narcolepsy. The study will enroll approximately 60 patients and eligible&#xD;
      patients will be treated to receive either NLS-2 or placebo for 4-weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ESS Score From Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 4. A negative change from baseline represents improvement in excessive sleepiness.&#xD;
The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 4. PGIc is rated by subjects and measures the change in their condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Narcolepsy</condition>
  <condition>Excessive Daytime Sleepiness</condition>
  <condition>Cataplexy Narcolepsy</condition>
  <arm_group>
    <arm_group_label>NLS-2 (mazindol extended release)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 mg dosed orally, once daily for 1 week; followed by 3 mg dosed orally, once daily for up to 3 weeks (total of 4 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosed orally, once daily for up to 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mazindol extended release</intervention_name>
    <description>Dosed orally, once daily for up to 3 weeks</description>
    <arm_group_label>NLS-2 (mazindol extended release)</arm_group_label>
    <other_name>NLS-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosed orally, once daily for up to 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males and females between 18 and 65 years of age, inclusive&#xD;
&#xD;
          -  Diagnosis of narcolepsy according to ICSD-3 (International Classification of Sleep&#xD;
             Disorders, 3rd Edition) or Diagnostic and Statistical Manual of Mental Disorders, 5th&#xD;
             Edition (DSM-5) criteria&#xD;
&#xD;
          -  Body mass index from 18 to 40 kg/m2, inclusive&#xD;
&#xD;
          -  Consent to use a medically acceptable method of contraception&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects who are pregnant, nursing, or lactating&#xD;
&#xD;
          -  Any other clinically relevant medical, behavioral, or psychiatric disorder other than&#xD;
             narcolepsy that is associated with excessive sleepiness&#xD;
&#xD;
          -  History or presence of bipolar disorder, bipolar related disorders, schizophrenia,&#xD;
             schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5&#xD;
             criteria&#xD;
&#xD;
          -  Use of any over-the-counter (OTC) or prescription medications that could affect the&#xD;
             evaluation of excessive sleepiness&#xD;
&#xD;
          -  Use of any medications that could affect the evaluation of cataplexy&#xD;
&#xD;
          -  Received an investigational drug in the past 30 days or five half-lives (whichever is&#xD;
             longer)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Camozzi, MD</last_name>
    <role>Study Director</role>
    <affiliation>NLS Pharmaceutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Franco</last_name>
    <phone>512-413-4550</phone>
    <email>jf@nls-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos Camozzi, MD</last_name>
    <phone>+41 79 120 57 40</phone>
    <email>cc@nls-pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sleep Disorders Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>205-599-1020</phone>
      <phone_ext>122</phone_ext>
      <email>wbooth@sleepalabama.com</email>
    </contact>
    <investigator>
      <last_name>Robert Doekel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sleep Medicine Specialists of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-994-1825</phone>
      <email>info@southfloridasleeps.com</email>
    </contact>
    <investigator>
      <last_name>Edward Mezerhane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-851-9934</phone>
      <email>sdale@neurotrials.com</email>
    </contact>
    <investigator>
      <last_name>Russell Rosenberg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>678-782-5358</phone>
    </contact>
    <investigator>
      <last_name>Phillip Nowlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience Clinical Research Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>808-564-6141</phone>
      <email>Info@HawaiiNeuroscience.com</email>
    </contact>
    <investigator>
      <last_name>Kore Liow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center For Sleep &amp; Wake Disorders</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>301-654-1575</phone>
      <email>mail@sleepdoc.com</email>
    </contact>
    <investigator>
      <last_name>Helene Emsellem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sleep and Attention Disorders</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>586-254-0707</phone>
    </contact>
    <investigator>
      <last_name>Bart Sangal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Sleep Specialists</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-707-4120</phone>
    </contact>
    <investigator>
      <last_name>Daniel Garber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Respiratory and Sleep Medicine</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-248-0000</phone>
    </contact>
    <investigator>
      <last_name>Thomas Stern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intrepid Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>513-977-8888</phone>
    </contact>
    <investigator>
      <last_name>Bruce Corser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bogan Sleep Consultants</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>803-251-3093</phone>
    </contact>
    <investigator>
      <last_name>Richard Bogan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy &amp; Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>726-444-5230</phone>
      <email>rafati.sue@sleeptrc.com</email>
    </contact>
    <investigator>
      <last_name>James Andry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mazindol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

